Kangmei Pharmaceutical Hits Day Low at CNY 1.79 Amid Price Pressure

Kangmei Pharmaceutical Co., Ltd. experienced a significant decline today, with the stock dropping by 4.79% and reaching an intraday low of CNY 1.79. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by only 1.24% on the same day. Over the past week, Kangmei has seen a decrease of 4.28%, while its monthly performance reflects a decline of 5.29%. Year-to-date, the stock is down 6.28%, and its one-year performance shows a notable drop of 19.0%. The company's long-term growth metrics indicate challenges, with net sales growing at an annual rate of just 0.67% over the last five years, and a significant decline in pre-tax profit and net profit reported in the latest quarter. Kangmei's return on equity stands at 0.27%, and it carries a price-to-book ratio of 3.58, suggesting a relatively high valuation compared to its financial performance. The company continues to face consistent underperformance against the China Shanghai Composite over the last three years, highlighting ongoing difficulties in the competitive pharmaceuticals and biotechnology sector.